Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451175 | 0.88 | GPR119 (0.43) | GPR119HPGDRECQLEPHX1STS | |
| SCHEMBL6450266 | 0.82 | HPGD (0.47) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL310750 | 0.79 | GPR119 (0.57) | GPR119 | |
| SCHEMBL8430979 | 0.79 | HPGD (0.47) | GPR119HPGDRECQLEPHX1STS | |
| SCHEMBL6456079 | 0.79 | HPGD (0.49) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL6446543 | 0.79 | GPR119 (0.44) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL27120710 | 0.78 | HPGD (0.48) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL21828491 | 0.77 | GPR119 (0.49) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL1295880 | 0.77 | GPR119 (0.64) | GPR119 | |
| SCHEMBL6449345 | 0.77 | RECQL (0.42) | GPR119HPGDRECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117917410-A | Pan-KRAS degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-04-23 | — | — | CN | disclosed |
| US-6964974-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | GPR119 30/4885HPGD 43/4885RECQL 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.